Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zika virus-specific ostrich IgY antibody is a **preclinical ostrich-derived polyclonal antibody program** from Ostrich Pharma for **Zika virus infection**. The product consists of **IgY antibodies isolated from egg yolks of immunized ostriches** and is intended to **bind and neutralize Zika virus directly**, thereby reducing viral infectivity. Based on the provided pipeline context, the program is listed as a **partner collaboration** and has **no disclosed brand name or development code**. The modality is a pathogen-targeting biologic rather than a conventional small molecule, and the available description indicates development remains at the **preclinical** stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zika virus-specific ostrich IgY antibody.